Pharmacoeconomic Evaluations of Oral Anticancer Drugs
a Systematic Review
,
Abstract
Background: Oral anticancer drugs (OACDs) have been used since the 1950s and are expected to be linked with enhanced life quality which helps patients receive treatment at home. Although more convenient in use than intravenous or other infused drugs, the high costs of these OACDs have been proven controversial. Methods: The literature was searched systematically from PubMed, Cochrane, Embase, and Scopus according to the PRISMA guidelines. The inclusion criteria included studies in the English language, evaluating Pharmacoeconomics, and evaluating cost-utility and cost-effectiveness related to OACDs. The information on the included studies was synthesized in the form of summary tables. Results: Thirteen studies were included for quantitative analysis, which evaluated the costs or cost-effectiveness of different OACDs used for various types of cancer. It was found that the average cost for the OACDs was $80979/year in attaining (quality-adjusted life per year) QALY across different countries. The costs of different OACDs were highly varied alone in the US. The included studies' results were highly varied, limiting the findings' interpretations. Conclusion: Various studies about cost-effectiveness persist insufficiently represented in the literature regarding OACDs, suggesting the requirement of more cost-effectiveness analysis shortly. The increased costs of these OACDs require careful evaluation of the cost-effectiveness studies.Al Kadour, A., Al Marridi, W., & Al-Badriyeh, D. (2018). Pharmacoeconomics evaluations of oral anticancer agents: systematic review of characteristics, methodological trends, and reporting quality. Value in Health Regional Issues, 16, 46-60. PMID: 30144775 DOI: 10.1016/j.vhri.2018.05.003
Annemans, L. (2008). Methodological Issues in Evaluating Cost-effectiveness of Adjuvant Aromatase Inhibitors in Early Breast Cancer. Pharmacoeconomics, 26(5), 409-423.
Bussabawalai, T., Thiboonboon, K., & Teerawattananon, Y. (2019). Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand. Cost-effectiveness and Resource Allocation, 17(1), 1. PMID: 30636935 PMCID: PMC6323771 DOI: 10.1186/s12962-018-0169-9
Carr, B. I., Carroll, S., Muszbek, N., & Gondek, K. (2010). Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. Journal of gastroenterology and hepatology, 25(11), 1739-1746.
Charles, J., & Edwards, R. T. (2016). A guide to health economics for those working in public health: Centre for Health Economics and Medicines Evaluation, Bangor University.
Cheema, P., Gavura, S., Migus, M., Godman, B., Yeung, L., & Trudeau, M. (2012). International variability in the reimbursement of cancer drugs by publically funded drug programs. Current oncology, 19(3), 165-176.
Chen, Z., Wang, C., Xu, X., & Feng, W. (2009). Cost-Effectiveness Study Comparing Imatinib with Interferon-α for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Health-Care System Perspective (CPHSP). Value in Health, 12, S85-S88. doi:https://doi.org/10.1111/j.1524-4733.2009.00635.x
Cleemput, I., Neyt, M., Thiry, N., De Laet, C., & Leys, M. (2011). Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. International journal of technology assessment in health care, 27(1), 71-76.
Contreras-Hernandez, I., Mould-Quevedo, J., Silva, A., Salinas-Escudero, G., Villasis-Keever, M., Granados-Garcia, V., . . . Garduno-Espinosa, J. (2008). A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours. British journal of cancer, 98(11), 1762-1768.
Danzon, P. M., & Furukawa, M. F. (2008). International prices and availability of pharmaceuticals in 2005. Health affairs, 27(1), 221-233.
Delea, T. E., Tappenden, P., Sofrygin, O., Browning, D., Amonkar, M. M., Karnon, J., . . . Cameron, D. (2012). Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab. The European Journal of Health Economics, 13(5), 589-603. doi:10.1007/s10198-011-0323-1
Drummond, M. F., & Jefferson, T. (1996). Guidelines for authors and peer reviewers of economic submissions to the BMJ. Bmj, 313(7052), 275-283.
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes: Oxford university press.
Ebara, T., Ohno, T., & Nakano, T. (2013). Quantitative medical cost-effectiveness analysis of molecular-targeting cancer drugs in Japan. DARU Journal of Pharmaceutical Sciences, 21(1), 1-6.
Frederix, G. W., Severens, J. L., Hövels, A. M., Raaijmakers, J. A., & Schellens, J. H. (2012). Reviewing the cost-effectiveness of endocrine early breast cancer therapies: influence of differences in modeling methods on outcomes. Value in Health, 15(1), 94-105.
Geynisman, D. M., & Wickersham, K. E. (2013). Adherence to targeted oral anticancer medications. Discovery medicine, 15(83), 231.
Ghatnekar, O., Hjalte, F., & Taylor, M. (2010). Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model application. Acta Oncologica, 49(6), 851-858. doi:10.3109/0284186X.2010.495132
Goldstein, D. A., Clark, J., Tu, Y., Zhang, J., Fang, F., Goldstein, R., . . . Rosenbaum, E. (2017). A global comparison of the cost of patented cancer drugs in relation to global differences in wealth. Oncotarget, 8(42), 71548.
Hirschfeld, S., Ho, P. T., Smith, M., & Pazdur, R. (2003). Regulatory approvals of pediatric oncology drugs: previous experience and new initiatives. Journal of clinical oncology, 21(6), 1066-1073.
Hoyle, M., Rogers, G., Moxham, T., Liu, Z., & Stein, K. (2011). Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia. Value in Health, 14(8), 1057-1067. doi:https://doi.org/10.1016/j.jval.2011.07.006
John-Baptiste, A. A., Wu, W., Rochon, P., Anderson, G. M., & Bell, C. M. (2013). A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One, 8(5), e62614.
Kantarjian, H., Mathisen, M. S., & Lipton, J. H. (2015). Having “skin in the game” and allowing cross-border importation of drugs to lower high prices of cancer drugs. JAMA oncology, 1(6), 729-730.
Kavookjian, J., & Wittayanukorn, S. (2015). Interventions for adherence with oral chemotherapy in hematological malignancies: a systematic review. Research in Social and Administrative Pharmacy, 11(3), 303-314.
Kefford, R. F. (2012). Drug treatment for melanoma: progress, but who pays? Medical Journal of Australia, 197(4), 198.
Krol, M., Koopman, M., Uyl-de Groot, C., & Punt, C. J. (2007). A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert opinion on pharmacotherapy, 8(9), 1313-1328.
Laupacis, A. (2009). Evidence and Values: Requirements for Public Reimbursement of Drugs for Rare Diseases-A Case Study in Oncology-Reply. Journal of Population Therapeutics and Clinical Pharmacology, 16(2).
Le, Q. A., & Hay, J. W. (2009). Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer. Cancer, 115(3), 489-498.
Leukemia, E. i. C. M. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, The Journal of the American Society of Hematology, 121(22), 4439-4442.
Leung, H. W., Chan, A. L., Leung, M. S., & Lu, C.-L. (2013). Systematic review and quality assessment of cost-effectiveness analysis of pharmaceutical therapies for advanced colorectal cancer. Annals of Pharmacotherapy, 47(4), 506-518.
Levit, L. A., Balogh, E., Nass, S. J., & Ganz, P. (2013). Delivering high-quality cancer care: charting a new course for a system in crisis: National Academies Press Washington, DC.
Liao, W., Xu, H., Hutton, D., Wu, Q., Zhou, K., Luo, H., . . . Wen, F. (2021). Cost-Effectiveness Analysis of Fourth-or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors. Frontiers in Oncology, 11, 692005-692005.
Majer, I. M., Gelderblom, H., van den Hout, W. B., Gray, E., & Verheggen, B. G. (2013). Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial. Journal of Medical Economics, 16(9), 1106-1119. doi:10.3111/13696998.2013.819357
Mitsiades, N. (2013). A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer research, 73(15), 4599-4605.
Moher, D., Altman, D. G., Liberati, A., & Tetzlaff, J. (2011). PRISMA statement. Epidemiology, 22(1), 128.
O'SBrien, S. G. (2001). Imatinib for chronic myeloid leukaemia: a NICE mess. The Lancet, 358(9296), 1902-1903.
Pavey, T., Hoyle, M., Ciani, O., Crathorne, L., Jones-Hughes, T., Cooper, C., . . . Ukoumunne, O. (2012). Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technology Assessment (Winchester, England), 16(42), iii-iv, 1.
Piccaluga, P. P., Rondoni, M., Paolini, S., Rosti, G., Martinelli, G., & Baccarani, M. (2007). Imatinib mesylate in the treatment of hematologic malignancies. Expert Opinion on Biological Therapy, 7(10), 1597-1611.
Reed, S. D., Anstrom, K. J., Li, Y., & Schulman, K. A. (2008). Updated Estimates of Survival and Cost-effectiveness for Imatinib versus Interferon-a Plus Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukaemia. Pharmacoeconomics, 26(5), 435-446. doi:10.2165/00019053-200826050-00007
Richon, V. M. (2010). Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics, 2(3), 457-465.
Santos, A. S., Guerra-Junior, A. A., Godman, B., Morton, A., & Ruas, C. M. (2018). Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert review of pharmacoeconomics & outcomes research, 18(3), 277-288.
Saxton, A. T., Poenaru, D., Ozgediz, D., Ameh, E. A., Farmer, D., Smith, E. R., & Rice, H. E. (2016). Economic analysis of children’s surgical care in low-and middle-income countries: a systematic review and analysis. PLoS One, 11(10), e0165480.
Schott, S., Schneeweiss, A., Reinhardt, J., Bruckner, T., Domschke, C., Sohn, C., & Eichbaum, M. H. (2011). Acceptance of oral chemotherapy in breast cancer patients-a survey study. BMC cancer, 11(1), 1-10.
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., . . . Kristjansson, E. (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj, 358.
Shen, C., Chien, C.-R., Geynisman, D. M., Smieliauskas, F., & Shih, Y.-C. T. (2014). A review of economic impact of targeted oral anticancer medications. Expert review of pharmacoeconomics & outcomes research, 14(1), 45-69.
Shih, Y.-C. T., Ganz, P. A., Aberle, D., Abernethy, A., Bekelman, J., Brawley, O., . . . Temel, J. S. (2013). Delivering high-quality and affordable care throughout the cancer care continuum. Journal of clinical oncology, 31(32), 4151.
Shih, Y.-C. T., Xu, Y., Liu, L., & Smieliauskas, F. (2017). Rising prices of targeted oral anticancer medications and associated financial burden on Medicare beneficiaries. Journal of clinical oncology, 35(22), 2482.
Smieliauskas, F., Chien, C.-R., Shen, C., Geynisman, D. M., & Shih, Y.-C. T. (2014). Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics, 32(7), 651-680.
Sohi, G. K., Levy, J., Delibasic, V., Davis, L., Mahar, A., Amirazodi, E., . . . Mittmann, N. (2020). The cost of chemotherapy administration: A systematic review and meta-analysis: American Society of Clinical Oncology.
Takeda, A., Jones, J., Loveman, E., Tan, S., & Clegg, A. (2007). The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England), 11(19), iii, ix-xi, 1.
Truong, J., Chan, K. K., Mai, H., Chambers, A., Sabharwal, M., Trudeau, M. E., & Cheung, M. C. (2019). The impact of pricing strategy on the costs of oral anti‐cancer drugs. Cancer medicine, 8(8), 3770-3781.
Vogler, S., & Vitry, A. (2016). Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. The Lancet Oncology, 17(1), 39-47.
Ward, S., Simpson, E., Davis, S., Hind, D., Rees, A., & Wilkinson, A. (2007). Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technology Assessment (Winchester, England), 11(40), 1-144.
Yeung, K., & Carlson, J. J. (2012). Clinical and economic review of erlotinib in non-small-cell lung cancer. Expert review of pharmacoeconomics & outcomes research, 12(4), 411-423.
Zhu, Y. X., Kortuem, K. M., & Stewart, A. K. (2013). Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leukemia & lymphoma, 54(4), 683-687.
| Files | ||
| Issue | Vol 9 No 2 (2023) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/jppm.v9i2.13370 | |
| Keywords | ||
| Pharmacoeconomics Oral anticancers Systematic review Cost analysis | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
